pharma · Nasopharyngeal Carcinoma · Hepatocellular Carcinoma
Chinese Academy of
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Chinese Academy of is a pharma organization headquartered in TAIZHOU, CN. Primary therapeutic focus areas include Nasopharyngeal Carcinoma, Hepatocellular Carcinoma, COVID-19, Breast Cancer, Coronary Artery Disease. Nova
China, TAIZHOU, CN HQ
170 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- China, TAIZHOU, CN
- Employees
- 170
- Programs
- 1328
- Drugs
- 711
- Patents
- 335
REC611-IIT-1
Phase 1 · mab · Prevention of COVID-19 Caused by SARS-CoV-2
REC611-IIT-1 for Prevention of COVID-19 Caused by SARS-CoV-2 is a Phase 1 program (mab) at Xiyuan Hospital of China Academy of Chinese Medical Sciences with 1 ClinicalTrials.gov record(s).
Internal code REC611-IIT-1
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Xiyuan Hospital of China Academy of Chinese Medical Sciences
- Phase
- Phase 1
- Modality
- mab
- Indication
- Prevention of COVID-19 Caused by SARS-CoV-2
- Status
- active
- Trials
- 1